Neil Dahiya

EMA Panel Endorses Palforzia Indication Expansion for Toddler Peanut Allergy Treatment

Stallergenes Greer, a firm dedicated to allergen immunotherapy (AIT) solutions, has announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has given a favorable opinion for broadening Palforzia’s existing use. This development is directed towards

EMA Panel Endorses Palforzia Indication Expansion for Toddler Peanut Allergy Treatment Read More »

BioNxt Solutions Unveils Sublingual Thin-Film ODF for Semaglutide Development

BioNxt Solutions Inc., specializing in cutting-edge drug delivery technologies, has announced its latest project: a sublingual thin-film oral dissolvable film (ODF) for Semaglutide, labeled internally as BNT24005. This groundbreaking product aims to enhance the current administration techniques developed by Novo

BioNxt Solutions Unveils Sublingual Thin-Film ODF for Semaglutide Development Read More »

AAVB-081 Receives Rare Disease Status from US FDA for Usher Syndrome Type 1B Retinitis Pigmentosa Treatment

AAVantgarde Bio, a clinical-stage biotech firm headquartered in Italy, revealed that the US Food and Drug Administration (FDA) has awarded Orphan Drug Status to its leading initiative, AAVB-081, aimed at treating Usher Syndrome Type 1B (USH1B) retinitis pigmentosa. “Individuals with

AAVB-081 Receives Rare Disease Status from US FDA for Usher Syndrome Type 1B Retinitis Pigmentosa Treatment Read More »

Endo Launches FDA-Approved Ready-to-Use Adrenalin Premixed IV Bag in the USA

Endo, Inc., a versatile company specializing in pharmaceuticals, has unveiled its new Adrenalin premixed bag, marking the first ever epinephrine in 0.9% sodium chloride injection that is FDA-approved and manufacturer-prepared for intravenous (IV) use. “This groundbreaking ready-to-use bag of epinephrine

Endo Launches FDA-Approved Ready-to-Use Adrenalin Premixed IV Bag in the USA Read More »

PTC and Novartis Form Global Partnership for Huntington’s Disease Treatment PTC518

PTC Therapeutics, Inc., a globally recognized biopharmaceutical firm, has entered into a worldwide license and collaboration agreement with Novartis Pharmaceuticals Corporation, a division of Novartis AG. This partnership centers on PTC518, a program designed to innovate treatment for Huntington’s disease,

PTC and Novartis Form Global Partnership for Huntington’s Disease Treatment PTC518 Read More »